Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Gut
Main Authors: Welzel, Tania M, Nelson, David R, Morelli, Giuseppe, Di Bisceglie, Adrian, Reddy, Rajender K, Kuo, Alexander, Lim, Joseph K, Darling, Jama, Pockros, Paul, Galati, Joseph S, Frazier, Lynn M, Alqahtani, Saleh, Sulkowski, Mark S, Vainorius, Monika, Akushevich, Lucy, Fried, Michael W, Zeuzem, Stefan
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2017
Teme:
Hepatology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595101/
https://ncbi.nlm.nih.gov/pubmed/27418632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-311609
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki